Teladoc Health Inc. (TDOC) saw its stock soar 5.20% during intraday trading on Thursday, following the announcement of a pharmacy integration agreement with Eli Lilly's LillyDirect pharmacy partner, Gifthealth. This agreement will provide Teladoc Health members enrolled in its Comprehensive Weight Care Program with access to the FDA-approved obesity drug Zepbound® (tirzepatide) through a self-pay option.
The integration with Gifthealth allows eligible Teladoc Health members without insurance coverage for glucagon-like peptide-1 receptor agonists (GLP-1s) for obesity to have single-use Zepbound® vials delivered directly to their homes. This move aims to reduce barriers to high-quality care and help members afford transformative FDA-approved treatments while avoiding the potential risks of compounded medications.
In addition to clinically appropriate medication access, Teladoc Health's Comprehensive Weight Care Program offers a multi-disciplinary, evidence-based approach with support from licensed clinicians, registered dietitians, and expert health coaches. Members receive personalized lifestyle coaching, nutrition counseling, mental health support, and proven behavior change resources to help manage and maintain a healthy weight.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。